The Center for Biosimilars® recaps the top stories for the week of February 24, 2020.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 24, 2020.
Number 5: A new review analyzing the risk of cancer in patients with psoriasis found no increased risk for those treated with biologics.
Number 4: The FDA amends the definition of “biological product” in its final rule regarding the regulatory shift that begins March 23, when insulin and other biological products shift to a different approval pathway.
Number 3: A year-in-review article outlines 2019 studies about nonmedical switching and finds evidence to support moving from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Number 2: AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira sales decline and more adalimumab biosimilars to the blockbuster arthritis drug enter international markets.
Number 1: The launch of Pfizer’s trastuzumab biosimilar, Trazimera, means the originator product Herceptin now has 3 biosimilar competitors.
To read all of these articles and more, visit centerforbiosimilars.com.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.